264 related articles for article (PubMed ID: 24752235)
21. Breast cancer prognostic biomarker using attractor metagenes and the FGD3-SUSD3 metagene.
Ou Yang TH; Cheng WY; Zheng T; Maurer MA; Anastassiou D
Cancer Epidemiol Biomarkers Prev; 2014 Dec; 23(12):2850-6. PubMed ID: 25249324
[TBL] [Abstract][Full Text] [Related]
22. A clinically relevant gene signature in triple negative and basal-like breast cancer.
Rody A; Karn T; Liedtke C; Pusztai L; Ruckhaeberle E; Hanker L; Gaetje R; Solbach C; Ahr A; Metzler D; Schmidt M; Müller V; Holtrich U; Kaufmann M
Breast Cancer Res; 2011 Oct; 13(5):R97. PubMed ID: 21978456
[TBL] [Abstract][Full Text] [Related]
23. Significance of E-cadherin expression in triple-negative breast cancer.
Kashiwagi S; Yashiro M; Takashima T; Nomura S; Noda S; Kawajiri H; Ishikawa T; Wakasa K; Hirakawa K
Br J Cancer; 2010 Jul; 103(2):249-55. PubMed ID: 20551954
[TBL] [Abstract][Full Text] [Related]
24. Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.
Shao F; Sun H; Deng CX
Oncotarget; 2017 Sep; 8(42):73329-73344. PubMed ID: 29069872
[TBL] [Abstract][Full Text] [Related]
25. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
[TBL] [Abstract][Full Text] [Related]
26. No association between triple-negative breast cancer and prognosis of patients receiving breast-conserving treatment.
Mu L; Liu Y; Xiao M; Liu W; Liu M; Wang X
Oncol Lett; 2017 Dec; 14(6):7862-7872. PubMed ID: 29250179
[TBL] [Abstract][Full Text] [Related]
27. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
Karn T; Pusztai L; Holtrich U; Iwamoto T; Shiang CY; Schmidt M; Müller V; Solbach C; Gaetje R; Hanker L; Ahr A; Liedtke C; Ruckhäberle E; Kaufmann M; Rody A
PLoS One; 2011; 6(12):e28403. PubMed ID: 22220191
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
Bianchini G; Iwamoto T; Qi Y; Coutant C; Shiang CY; Wang B; Santarpia L; Valero V; Hortobagyi GN; Symmans WF; Gianni L; Pusztai L
Cancer Res; 2010 Nov; 70(21):8852-62. PubMed ID: 20959472
[TBL] [Abstract][Full Text] [Related]
29. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
30. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM
Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894
[TBL] [Abstract][Full Text] [Related]
31. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
32. Association Between Plasma Diacetylspermine and Tumor Spermine Synthase With Outcome in Triple-Negative Breast Cancer.
Fahrmann JF; Vykoukal J; Fleury A; Tripathi S; Dennison JB; Murage E; Wang P; Yu CY; Capello M; Creighton CJ; Do KA; Long JP; Irajizad E; Peterson C; Katayama H; Disis ML; Arun B; Hanash S
J Natl Cancer Inst; 2020 Jun; 112(6):607-616. PubMed ID: 31503278
[TBL] [Abstract][Full Text] [Related]
33. Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression.
Hessel H; Poignée-Heger M; Lohmann S; Hirscher B; Herold A; Assmann G; Budczies J; Sotlar K; Kirchner T
J Cancer; 2018; 9(15):2589-2602. PubMed ID: 30087699
[No Abstract] [Full Text] [Related]
34. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
35. Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.
Callari M; Cappelletti V; D'Aiuto F; Musella V; Lembo A; Petel F; Karn T; Iwamoto T; Provero P; Daidone MG; Gianni L; Bianchini G
Clin Cancer Res; 2016 Jan; 22(2):337-45. PubMed ID: 26423797
[TBL] [Abstract][Full Text] [Related]
36. Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization against PARP1 Inhibition in a Replication-Dependent Manner.
Rieckhoff J; Meyer F; Classen S; Zielinski A; Riepen B; Wikman H; Petersen C; Rothkamm K; Borgmann K; Parplys AC
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33003585
[TBL] [Abstract][Full Text] [Related]
37. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes.
Smid M; Hoes M; Sieuwerts AM; Sleijfer S; Zhang Y; Wang Y; Foekens JA; Martens JW
Breast Cancer Res Treat; 2011 Jul; 128(1):23-30. PubMed ID: 20632083
[TBL] [Abstract][Full Text] [Related]
38. Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis.
Garg AD; De Ruysscher D; Agostinis P
Oncoimmunology; 2016 Feb; 5(2):e1069938. PubMed ID: 27057433
[TBL] [Abstract][Full Text] [Related]
39. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
40. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
